A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of ...
Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
March is the awareness month for colorectal cancer and multiple myeloma. If you’re interested in speaking to experts, contact media@fredhutch.org to schedule interviews. Scientists develop ...
A 55-year-old man developed painful swelling that doctors later thought was arthritis. Subtle clues revealed something more ...
Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...
After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...
If the rest of 2026 continues in this vein, we may look back on January and February as the moment the sector recognised that ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
(PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive ...
Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for ...
Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus, and other devastating autoimmune diseases – by reprogramming patients’ out-of-whack immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results